Skip to Main Content

Author Details

Kimberly Stegmaier
Dana-Farber Cancer Institute
1995
148
50
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36658220The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma.Nat Cell Biol2023
36398965Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Cancer Res2023
37747726EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.Cancer Res2023
37595362PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.Blood2023
37648673DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.Blood Adv2023
37725576Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.Clin Cancer Res2023
36823351Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor.Nat Chem Biol2023
37066194Rapid-kinetics degron benchmarking reveals off-target activities and mixed agonism-antagonism of MYB inhibitors.bioRxiv2023
37000878Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity.Sci Adv2023
37306107Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.Cancer Med2023
36739349Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.Leukemia2023
36993171Leukemia core transcriptional circuitry is a sparsely interconnected hierarchy stabilized by incoherent feed-forward loops.bioRxiv2023
36658220The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma.Nat Cell Biol2023
37595362PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.Blood2023
37747726EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.Cancer Res2023
37648673DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.Blood Adv2023
37725576Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.Clin Cancer Res2023
36993171Leukemia core transcriptional circuitry is a sparsely interconnected hierarchy stabilized by incoherent feed-forward loops.bioRxiv2023
37306107Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.Cancer Med2023
37000878Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity.Sci Adv2023
37066194Rapid-kinetics degron benchmarking reveals off-target activities and mixed agonism-antagonism of MYB inhibitors.bioRxiv2023
36398965Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Cancer Res2023
36739349Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.Leukemia2023
36823351Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor.Nat Chem Biol2023
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35710782Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.Cell Death Dis2022
35709529Transcriptional Plasticity Drives Leukemia Immune Escape.Blood Cancer Discov2022
36305736BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.Cancer Discov2022
36040810VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.JCI Insight2022
36221002Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group.Br J Cancer2022
35817829Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.Nat Cancer2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35405016Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.Cancer Discov2022
35534777IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.Nat Cancer2022
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35298000Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.Mol Cancer Res2022
34624079SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.Blood2022
35245447The proteogenomic subtypes of acute myeloid leukemia.Cancer Cell2022
34772733EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.Cancer Discov2022
34531254An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.Cancer Discov2022
35710782Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.Cell Death Dis2022
35709529Transcriptional Plasticity Drives Leukemia Immune Escape.Blood Cancer Discov2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35405016Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.Cancer Discov2022
35534777IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.Nat Cancer2022
35817829Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.Nat Cancer2022
36040810VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.JCI Insight2022
36305736BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.Cancer Discov2022
36221002Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group.Br J Cancer2022
35245447The proteogenomic subtypes of acute myeloid leukemia.Cancer Cell2022
  • 1 - 50 of 296

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 9
Chelsea Mayoh
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2016
Number of shared co-authors 11
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 6
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 24
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 7
Henry Yang
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 12
Didier Surdez
Balgrist University Hospital, University of Zurich (UZH)
Career Start Year 2005
Number of shared co-authors 35
Richard Koche
Memorial Sloan Kettering Cancer Center
Career Start Year 2005
Number of shared co-authors 12
Aniruddha J Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2004
Number of shared co-authors 7
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 3
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 8
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 8
Laura Riva
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2003
Number of shared co-authors 3
Michelle J Henderson
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2002
Number of shared co-authors 3
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 21
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 3
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 7
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 31
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 15
Olaf Witt
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1993
Number of shared co-authors 28
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 17
Javed Khan
Center for Cancer Research, National Cancer Institute
Career Start Year 1993
Number of shared co-authors 49
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 15
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 15
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 8
Glenn M Marshall
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 8
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1987
Number of shared co-authors 19
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 20

Collaborators

Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 42
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 28
Giovanni Roti
University of Parma
Co-authored papers 19
Yana Pikman
Dana Farber Cancer Institute
Co-authored papers 18
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 17
Francisca Vazquez
Broad Institute of MIT and Harvard
Co-authored papers 17
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 16
Brian D Crompton
Co-authored papers 14
David E Root
Broad Institute of Harvard and MIT
Co-authored papers 14
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 14
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 13
Aviad Tsherniak
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard
Co-authored papers 13
Jun Qi
Dana-Farber Cancer Institute
Co-authored papers 11
Federica Piccioni
Co-authored papers 11
Stephen L Lessnick
The Ohio State University College of Medicine
Co-authored papers 10
Charles W M Roberts
Co-authored papers 9
Nathanael S Gray
Harvard Medical School
Co-authored papers 9
Angela Su
The Broad Institute of MIT and Harvard
Co-authored papers 9
Katherine A Janeway
Co-authored papers 9
James E Bradner
Co-authored papers 9
Steven G DuBois
Co-authored papers 8
Guillaume Kugener
Keck School of Medicine of the University of California los angeles
Co-authored papers 8
Jesse S Boehm
Broad Institute of Harvard and MIT
Co-authored papers 7
Aaron R Thorner
Co-authored papers 7
Glenn S Cowley
Broad Institute of Harvard and MIT
Co-authored papers 7
Donna Neuberg
Co-authored papers 7
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 7
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 7
Jaume Mora
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Co-authored papers 6
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 6
Release 1.2